Public News Service on MSN
Immunotherapy cancer treatment proves promising at Duke University
As colon cancer rates among people younger than 50 skyrocket, a new clinical trial that uses immunotherapy, rather than ...
A study demonstrates that levels of the CTHRC1 protein in tumor-associated fibroblasts can predict immunotherapy outcomes in ...
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to ...
At present, only around 5% of patients with colon cancer are candidates for immunotherapy. This new biomarker could make it possible to determine more accurately which individuals may receive this ...
After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – ...
ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than 50. While colon cancer ...
HALIFAX, NS, April 13, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to provide follow-up histology tissue analysis data from its first-in-human early ...
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is excited to announce publication of a preclinical ...
PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...
Spencer Laird first noticed blood in his stool when he was 25. His doctor thought it was hemorrhoids caused by his work as a mechanic. Eighteen months later, a colonoscopy found colorectal cancer, ...
The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results